List view / Grid view
10 March 2016 | By Victoria White
Teva is to support IVF-Worldwide with a research grant to improve knowledge of fertility preservation protocols for women diagnosed with cancer...
Mega mergers, 3D printed drugs, a call for action on antimicrobial resistance: 2015 certainly was an interesting year for the pharmaceutical industry. Here we pick a selection of the top stories that hit the headlines.
2 October 2015 | By Victoria White
Through the Rimsa acquisition, Teva will become a leading pharmaceutical company in the second largest market in Latin America...
28 July 2015 | By Victoria White
Teva has successfully filed a MAA with the EMA for reslizumab -a humanised anti-IL-5 monoclonal antibody for the treatment of inadequately controlled asthma...
28 July 2015 | By Victoria White
Following yesterday’s news that Teva is to acquire Allergan’s global generics business, Teva has withdrawn its cash and stock proposal to acquire Mylan...
27 July 2015 | By Victoria White
Allergan followed an announcement it made yesterday about its acquisition of Naurex with news today that it is to divest its generics business to Teva...
9 July 2015 | By Victoria White
Teva has launched generic Axert® (almotriptan malate) tablets in the US for the treatment of migraine attacks in adults and adolescents...
2 July 2015 | By Victoria White
Teva’s DuoResp Spiromax inhaler for patients with asthma and COPD has won silver at the 2015 Medical Design Excellence Awards (MDEA)...
1 July 2015 | By Victoria White
Teva and Xenon have reported top line results from a Phase 2b study designed to evaluate the safety and efficacy of TV-45070 in patients with osteoarthritis...
1 July 2015 | By Victoria White
Teva Europe has announced the first European launches of its extended-regimen oral contraceptive, Seasonique for the prevention of pregnancy...
25 June 2015 | By Victoria White
The patient enrollment for the Phase III CONCERTO trial of laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS) has been finalised...
16 June 2015 | By Victoria White
Teva has announced positive top-line results from a study designed to evaluate the efficacy of SD-809 in the treatment of tardive dyskinesia...
15 June 2015 | By
The US Food and Drug Administration (FDA) has accepted for review Teva’s Biologics License Application (BLA) for reslizumab...
14 May 2015 | By Victoria White
Teva will present further data from its chronic migraine Phase IIb study of TEV-48125 at the 17th Congress of the International Headache Society on Friday...
6 May 2015 | By Victoria White
Teva has acquired Auspex Pharmaceuticals through the successful tender offer for all of the outstanding Auspex shares at $101.00 per share...
